Cheng CF, et al. - A total of 5,388 SLE people who fulfilled the 1997 American College of Rheumatology SLE criteria and presented with definite TB screened, and 30 individuals were recruited in order to ascertain whether prednisolone dose during treatment of tuberculosis could be a risk factor for mortality in people with SLE. In comparison with the survival group, individuals in the mortality group had notably more central nervous system involvement of TB, higher Systemic Lupus Erythematosus Disease Activity Index-2000 scores and more cyclophosphamide use prior to TB, and greater prednisolone dose prior to and during TB treatment. In conclusion, for SLE individuals, for mortality, prednisolone dose during TB treatment is an independent risk factor. Moreover, in these individuals, keeping the prednisolone dose at less than 25 mg per day during TB treatment could be a sensible approach.